Avanir Pharmaceuticals, Inc.

AFFINIA

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

AVANIR

pharmaceutical preparations for the treatment of pain;

AVANIR

Pharmaceutical preparations for the treatment of neurological and psychiatric disorders;

CENEDEX

Pharmaceutical preparations for the treatment and rehabilitation of neurological disorders;

CENEXA

Pharmaceutical preparations for the treatment and rehabilitation of neurological disorders;

CENVIA

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

DECASO

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

DYNAERO

Medical devices and instruments, namely, devices for nasal delivery of powder substances; powder delivery devices for nasal delivery of powder substances; nebulizer devices for nasal delivery of substances; intranasal delivery devices;

LEVIEM

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

MODEXAL

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

NAVIEX

Medical devices and instruments, namely, devices for nasal delivery of powder substances; powder delivery devices for nasal delivery of powder substances; nebulizer devices for nasal delivery of substances; intranasal delivery devices;

NEUDEXTA

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

NEURESA

Pharmaceutical preparations for the treatment and rehabilitation of neurological disorders;

NEURODEX

Pharmaceutical preparations for the treatment and rehabilitation of neurological disorders.;

NUEDEXTA

Line 5, Pharmaceutical preparations for the treatment of pain should be deleted.;Pharmaceutical preparations for the treatment and rehabilitation of neurological disorders;

NUEDEXTA

Pharmaceutical preparations for the treatment of pain;

PROMTIVA

Pharmaceutical preparations and substances for the treatment and/or alleviation of migraine; antimigraine triptans; sumatriptan;

SIGRIA

Pharmaceutical preparations for the treatment of pain and for the treatment and rehabilitation of neurological disorders;

SPELIFA

Pharmaceutical preparations and substances for the treatment and/or alleviation of migraine; antimigraine triptans; sumatriptan;

TRIAD

Printed materials, namely, books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, and pharmaceutical preparations and substances; printed instructional, educational and teaching material in the fields of clinical trials and pharmaceutical preparations and substances;Providing a web site featuring consumer information regarding clinical trials and pharmaceutical preparations;Providing medical information, consultancy and advisory services; providing a web site featuring medical information; Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, namely, pharmaceutical advice, medical and pharmaceutical consultation; providing information and advice in the fields of Alzheimer's disease, dementia and neurological disorders and conditions;Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; Providing a web site featuring scientific research information about investigational drugs;

TRIAD

The mark consists of a spherical design to the left of the word TRIAD.;Printed materials, namely, books, periodicals, journals, magazines, newsletters and reports featuring information and promotional materials relating to clinical trials, and pharmaceutical preparations and substances; printed instructional, educational and teaching material in the fields of clinical trials and pharmaceutical preparations and substances;Color is not claimed as a feature of the mark.;Providing a website featuring consumer information regarding clinical trials and pharmaceutical preparations;Providing medical information, consultancy and advisory services; providing a web site featuring medical information; Information and advisory services relating to pharmaceuticals, diseases and medical conditions and treatments, namely, pharmaceutical advice, medical and pharmaceutical consultation; providing information and advice in the fields of Alzheimer's disease, dementia and neurological disorders and conditions;Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; Providing a website featuring scientific research information about investigational drugs;